Keep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018
|
|
- Lydia Ferguson
- 5 years ago
- Views:
Transcription
1 Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets
2 Disclosures Nicole C. Pezzino declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.
3 Objectives Describe the evidence from clinical trials and noteworthy changes to the diabetes guidelines Evaluate patient cases to determine appropriate treatment options that focus on evidence-based recommendations Develop a individualized plan for implementation and follow-up for the patient
4 Who s in the room? Community Pharmacists? Ambulatory Care Pharmacists? Technicians? Hospital Pharmacists? Managed Care Pharmacists? Other?
5 How often do you interact with patients who have diabetes? Never Infrequently (1-4 times/month) Sometimes (5-10 times/month) Often (at least daily) Always (multiple times/ day)
6 Patient Case A patient presents to your community pharmacy diabetes clinic (you have a CPA for diabetes medications) with prescriptions for: 1. Metformin 850 mg by mouth once daily (#30; 5 RF) 2. Glipizide 10 mg by mouth once daily (#30; 5 RF) 3. Lantus 10 units subcutaneously at bedtime (#QS; 5 RF) 4. Alendronate 70 mg by mouth once weekly (#4; 5 RF) 5. Amlodipine 10 mg by mouth once daily (#30; 5 RF) 6. Hydrochlorothiazide 25 mg by mouth once daily (#30; 5 RF) She is a new patient to your pharmacy!
7 DOB: 1/27/1950 (68-years-old) Allergies: Sulfa drugs (hives) PMH: diabetes (10 years), hypertension (6 years), osteoarthritis (2 years) SHx: former smoker (30 PY; quit 10 years ago), denies alcohol and illicit drug use Relevant Labs (obtained 1/20/18): Glu: 208 mg/dl A1c: 8.9% K+: 4.2 meq/l BUN: 18 mg/dl Creatinine: 0.9 mg/dl creatinine, random urine: 310 mg/ dl Total Cholesterol: 188 mg/dl HDL: 29 mg/dl LDL: 123 mg/dl TG: 182 mg/dl
8 Nonprescription drugs: Aspirin 81 mg by mouth twice daily Cinnamon 1000 mg by mouth twice daily Fish Oil 1200 mg by mouth twice daily Calcium D-Glucarate 500 mg by mouth twice daily Vitamin D 2,000 units by mouth once daily (with breakfast) Melatonin 10 mg by mouth if needed for sleep Blood pressure: 148/92 mmhg (R arm, resting x10 minutes) Never graduated High School; SAHM Insurance: Geisinger Gold Standard Rx (Part D)
9 2018 Updates: American Diabetes Association
10 2018 by American Diabetes Association American Diabetes Association Dia Care 2018;41:S28-S37
11 2018 by American Diabetes Association American Diabetes Association Dia Care 2018;41:S28-S37
12 2018 by American Diabetes Association American Diabetes Association Dia Care 2018;41:S73-S85
13 2018 by American Diabetes Association American Diabetes Association Dia Care 2018;41:S73-S85
14 Technology General Update Resources added to various sections regarding the use of technology BeatO Log BG readings Diabetes Education Diabetes in Check Log BG + Meds & reminders Nutrition resources CDE Coaching Glooko Syncs to glucose meters Create charts MyFitnessPal Lifestyle app Log food & track nutrition facts
15 Section 1 Improving Care and Promoting Health in Populations Food insecurity Social Determinants of Health Housing stability Financial barriers Apply information to treatment decisions & refer to local community resources when available
16 Section 2 Classification and Diagnosis of Diabetes A1C limitations: Hemoglobin variants Assay interference Conditions with RBC turnover Utilize A1C test certified by NGSP and standardized to the Diabetes Control and Complications Trial (DCCT) Community screenings?
17 Section 9 Cardiovascular Disease and Risk Management Home BP monitoring Antihypertensive treatment approach Statin Use and Lipid management Agents that reduce cardiovascular events and/or mortality CVOT data on new diabetes agents + CVOT studies
18 Cardiovascular Outcomes Trials (CVOT)
19 DPP IV Inhibitor Cardiovascular Outcomes Trials SAVOR-TIMI 53 Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) Thrombolysis in Myocardial Infarction (TIMI) EXAMINE The Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Diabetes TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin
20 DPP IV Inhibitor Cardiovascular Outcomes Trials Trial Intervention; Number Diabetes duration; Median Follow-up Drug vs. Placebo (% Primary Endpoint) HR (95% CI) P value SAVOR- TIMI Saxagliptin/pl acebo N=16, yrs; 2.1 yrs 7.3 vs point MACE HR 1.00 ( ); P<0.001 NI P=0.99 Not Superior EXAMINE Alogliptin/pla cebo N=5, yrs; 1.5 yrs 11.3 vs point MACE HR 0.96 (95% UL < CI 1.16); P<0.001 NI P=0.32 Not Superior TECOS Sitagliptin/pla cebo N=14, yrs; 3.0 yrs 11.4 vs point MACE HR 0.98 ( ); P<0.001 NI P=0.65 Not Superior MACE: DPP-IV Inhibitors are noninferior to placebo; no superiority
21 GLP-1 RA Cardiovascular Outcomes Trials ELIXA Evaluation of Lixisenatide in Acute Coronary Syndrome LEADER Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results SUSTAIN-6 Trial to Evaluate Cardiovascular and Other Long-Term Outcomes with Semaglutide in Subjects with Type 2 Diabetes EXSCEL Exenatide Study of Cardiovascular Event Lowering
22 GLP-1 RA Cardiovascular Outcomes Trials Trial Intervention; Number Diabetes duration; Median F/U Drug vs. Placebo (% Primary Endpoint) HR (95% CI) P value ELIXA lixisenatide/plac ebo N=6, yrs; 2.1 yrs 13.4 vs point MACE ITT HR 1.02 ( ) P<0.001 NI P=0.81 Not Superior LEADER liraglutide/place bo N=9, yrs; 3.8 yrs 13.0 vs ITT HR 0.87 ( ) P<0.001 NI P=0.01 Superiority SUSTAIN-6 semaglutide/pla cebo N=3, yrs; 2.1 yrs 6.6 vs. 8.9 HR 0.74 ( ) P<0.001 NI P=0.02 Superiority EXSCEL exenatide/place bo N=14, yrs; 3.2 yrs 11.4 vs ITT HR 0.91 ( ) P<0.001 NI P=0.06 Not Superior
23 SGLT-2 Inhibitor Cardiovascular Outcomes Trials EMPA-REG: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes CANVAS, CANVAS-R: Canagliflozin Cardiovascular Assessment Study, Canagliflozin and Renal Events in Type 2 Diabetes
24 SGLT-2 Inhibitor Cardiovascular Outcomes Trials Trial Intervention; Number Diabetes duration; Median Follow-up Drug vs. Placebo (% Primary Endpoint) HR (95% CI) P value EMPA-REG empagliflozin /placebo N=7,020 57% >10 yrs 3.1 yrs 10.5% vs. 12.1% 3-point MACE HR 0.86 ( ) P<0.001 NI P=0.04 Superiority CANVAS/CA NVAS-R canagliflozin/ placebo N=4,330 N=5, yrs 5.7 yrs 2.1 yrs 9.8% vs. 10.1% 3- point MACE 89.4 vs (no. participants/1000 pt-yr) Progression to albuminuria HR 0.86 ( ) P<0.001 NI P=0.02 Superiority HR 0.73 (0.47=0.77) P=not stated
25 DEVOTE Insulin Cardiovascular Outcomes Trials Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events Trial Intervention; Number Diabetes duration; Median Follow-up Drug vs. Placebo (% Primary Endpoint) HR (95% CI) P value DEVOTE Degludec/gla rgine N=7,637 57% >10 yrs 3.1 yrs 8.5% vs. 9.3% (CV death, nonfatal MI/Stroke) HR 0.91 ( ) P< NI P=0.21 (Not Significant)
26 Which class would you recommend to be added to metformin? A. DPP-IV Inhibitor B. GLP-1 Analog C. SGLT-2 Inhibitor
27 Which of the following received the FDA expanded indication for CV safety in T2DM? A. Lixisenatide and linagliptin B. Exenatide and semaglutide C. Dapagliflozin and canagliflozin D. Liraglutide and empagliflozin
28 Summary Decrease CVD Risk No effect on CVD Risk
29 Individualized Diabetes Plans
30 Type 2 Diabetes Mellitus Secretagogues Sulfonylureas Acetohexamide Chlorpropamide Glimepiride* Glipizide* Glyburide* Tolazamide Tolbutamide Meglitinides Nateglinide Repaglinide Pharmacologic Treatment Oral Agents Antihyperglycemics Biguanides Metformin Thiazolidinediones Pioglitazone Roziglitazone α-glucosidase inhibitors Acarbose Miglitol DPP-4 inhibitors Sitagliptin Linagliptin Saxagliptin Alogliptin Injectable Agents Amylinomimetics Amylin analog Pramlintide Incretin Mimetics GLP-1 receptor agonist Exenatide (Immediate & Extended-Release) Liraglutide Albiglutide Dulaglutide Lixisenatide Semaglutide (approved Dec. 2017) Insulin Human Analog
31 Type 2 Diabetes Mellitus Pharmacologic Treatment Oral Agents Secretagogues Antihyperglycemics Bile Acid Sequestrants Colesevelam Dopamine Agonist Bromocriptine SGLT-2 Inhibitors Canagliflozin Dapagliflozin Empagliflozin Ertugliflozin* (coming January 2018)
32 Current Insulin Therapy Options Typ e Basal Insulin Prandial Insulin Premixed Insulin Human NPH U100 Regular human insulin U100 Regular human insulin U500 Insulin inhalation powder Analog Glargine U100 follow-on glargine U100 Glargine U300 Detemir U100 Degludec U100 Degludec U200 Lispro U100 Lispro U200 Aspart U100 Glulisine U100 Ultra rapid acting aspart (FIAsp) Regular human insulin 70/30 Lispro protamine + lispro 75/25 Lispro protamine + lispro 50/50 Aspart protamine + aspart 70/30 Insulin degludec + insulin aspart 70/30 Updated January 2018
33
34
35 Diabetes Medications and Their Effect on Blood Glucose Medication Alpha-glucosidase inhibitors Amylinomimetic (pramlintide) Biguanides (metformin) Bile Acid Sequestrants Dopamine agonists DPP-4 inhibitors GLP-1 agonists Meglitinides SGLT -2 Inhibitors Sulfonylureas TZDs Insulin (Basal) Insulin (Bolus) Effect on blood glucose Postprandial Postprandial Fasting Postprandial Postprandial Postprandial Short acting Postprandial Long acting Fasting and Postprandial Postprandial Fasting and Postprandial Fasting and Postprandial Fasting and Postprandial Fasting Postprandial Burke S, et al. Clinician Reviews. 2008;18:28-34.
36 Pharmacotherapy Options Islet b-cell Impaired Insulin Secretion Islet a-cell DPP4 Inhibitors GLP-1 Agonists Insulin Meglitinides Sulfonylureas Amylinomimetics DPP4 Inhibitors GLP-1 Agonists AGI Amylinomimetics Bile Acid Sequestrants GLP-1 Agonists Dietary Decreased Incretin Effect Increased Glucagon Secretion Increased HGP Neurotransmitter Dysfunction Amylinomimetics Biguanides DPP4 Inhibitors GLP-1 Agonists TZD s Amylinomimetics Dopamine Agonists GLP-1 Agonists Biguanide Insulin TZD s Biguanide Insulin TZD s SGLT-2 Inh Increased Lipolysis Decreased Glucose Uptake Increased Glucose Reabsorption
37 Patient Case 1
38 Patient Case A patient presents to your community pharmacy diabetes clinic (you have a CPA for diabetes medications) with prescriptions for: 1. Metformin 850 mg by mouth once daily (#30; 5 RF) 2. Glipizide 10 mg by mouth once daily (#30; 5 RF) 3. Lantus 10 units subcutaneously at bedtime (#QS; 5 RF) 4. Alendronate 70 mg by mouth once weekly (#4; 5 RF) 5. Amlodipine 10 mg by mouth once daily (#30; 5 RF) 6. Hydrochlorothiazide 25 mg by mouth once daily (#30; 5 RF) She is a new patient to your pharmacy!
39 DOB: 1/27/1950 (68-years-old) Allergies: Sulfa drugs (hives) PMH: diabetes (10 years), hypertension (6 years), osteoarthritis (2 years) SHx: former smoker (30 PY; quit 10 years ago), denies alcohol and illicit drug use Relevant Labs (obtained 1/20/18): Glu: 208 mg/dl A1c: 8.9% K+: 4.2 meq/l BUN: 18 mg/dl Creatinine: 0.9 mg/dl creatinine, random urine: 310 mg/ dl Total Cholesterol: 188 mg/dl HDL: 29 mg/dl LDL: 123 mg/dl TG: 182 mg/dl
40 Nonprescription drugs: Aspirin 81 mg by mouth twice daily Cinnamon 1000 mg by mouth twice daily Fish Oil 1200 mg by mouth twice daily Calcium D-Glucarate 500 mg by mouth twice daily Vitamin D 2,000 units by mouth once daily (with breakfast) Melatonin 10 mg by mouth if needed for sleep Blood pressure: 148/92 mmhg (R arm, resting x10 minutes) Never graduated High School; SAHM Insurance: Geisinger Gold Standard Rx (Part D)
41 What are you taking your medications for? My physician prescribes the prescription ones for my diabetes, high blood pressure and arthritis. I don t have any complaints about them.. I ve been taking them for a while now. I take my aspirin because I had a heart attack 5 years ago and I think the calcium goes with my arthritis medicines. I also see a chiropractor for my back pain and to help my joints, and he recommended most of my supplements I am taking.
42 Assessment 68 year-old female with uncontrolled Type 2 Diabetes Mellitus using metformin 850 mg, glipizide 10 mg and basal insulin to manage her diabetes Requires medication optimization and lifestyle modifications Financial considerations with her Medicare Plan
43 Assessment Does she require other medication interventions to meet the ADA 2018 Standards of Care? If she does, what other medication interventions is she a candidate for? ACEi/ARB microalbuminuria + BP Metformin dose Statin therapy clinical ASCVD Aspirin dose
44 Assessment Does she require any other non-medication related interventions to meet the ADA 2018 Standards of Care? If she does, what? Immunizations PCV13 PPSV23 (at least 5 years after previous PPSV23 dose) Annual influenza Hepatitis B 3 dose series (?) Medical Nutrition Therapy Referrals? Lab work?
45 Assessment What social determinants of health should we take into consideration with this patient case? Food insecurity Transportation Health Literacy Housing? Finances
46 Plan (Drug Therapy) Diabetes Nonprescription: Decrease Aspirin to once daily D/C Cinnamon and Fish Oil? Prescription: Metformin: increase dose to 2,000 mg daily D/C Glipizide (?) Plan to increase Lantus (insulin glargine) dose OR consider Xultophy (insulin degludec and liraglutide) Add empagliflozin vs. liraglutide?
47 Plan (Standards of Care) Optimize: Lifestyle: exercise + diet Candidate for high-intensity statin Albuminuria: initiate ACEi/ARB Vaccinations: PCV13 + PPSV23, Influenza, Hepatitis B(?) Confirm Appointments: Lab work? Follow-up appointments
48 Patient s Plan Goals of Therapy: Reduce the risk of cardiovascular events and keep blood glucose at/near normal levels Manage drug therapy to reduce the risk of adverse events Goals: A1C Goal: ADA <7% BG Goals: FBG mg/dl; PPG <180 mg/dl BP Goal: <140/90 mmhg Cholesterol Goal: appropriate statin therapy
49 Patient s Plan Drug Therapy: Could consider: Initiate Xultophy 100/3.6 (insulin degludec and liraglutide) titrated to 50 units Discontinue lantus + glipizide Increase metformin to 1,000 mg twice daily D/C Hydrochlorothiazide 25 mg and initiate Lisinopril 10 mg/hydrochorothiazide 25 mg Initiate atorvastatin mg Vaccines: Obtain patient s charts
50 Implementing the Plan (Education) Diet Reduce: saturated fat, trans fat and cholesterol intake Increase: dietary n-3 fatty acids, viscous fiber, plant stanols/sterols Physical Activity Low-impact, weight bearing exercise 150 minutes of aerobic activity Diabetes (in general) SMBG home monitoring Technology use??
51 Monitoring Xultophy Counseling on nausea & how to reduce Pen and needle use (rotate injection site no sharing, disposal) Hypoglycemia counseling Educate on goals and titrating dose Lisinopril/Hydrocholorthiazide: Home blood pressure monitoring Educate on goals Atorvastatin: Timing, side effect potential Follow-up lab work?
52 Evaluate & Monitor Short-term (1 to 3 months) Adverse events Adherence Follow-up appointment with physician (3 months) + a1c Confirm referrals Intermediate-term (3 to 12 months) Adherence to medication therapy Weight loss goals? Determine follow-up plan Long-term (12+ months) Follow-up lab work Confirm all interdisciplinary appointments
53 Key Points ADA 2018 Guidelines focus on individualization and evidencedbased recommendations including incorporation of medications with known cardiovascular benefit and the use of technology in diabetes management Empagliflozin and liraglutide received FDA approval for reduction of cardiovascular risk in patients with type 2 diabetes and preexisting heart disease Heart failure with DPP-IV inhibitors doesn t appear to be a class effect
54 Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets
What s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationNew Measure Recommended for Endorsement by PQA
New Measure Recommended for Endorsement by PQA Measure: Statin Use in Persons with Diabetes Description: The percentage of patients ages 40 75 years who were dispensed a medication for diabetes that receive
More informationPreventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm
Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Algorithm Updated 9/13/2017 PHASE Populations DM: type 2 ASCVD: hx heart attack/cad, CVA, TIA, AAA, Sx PAD Lifestyle Modifications
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More information2018 Diabetes Update
2018 Diabetes Update Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDE Susan Cornell, PharmD, CDE, FAPhA, FAADE Midwestern University Chicago College of Pharmacy Target Audience: Pharmacists ACPE#: 0202-0000-18-043-L01-P
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationHow to Use the ADA Type 2 Diabetes Treatment Algorithm. Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP
How to Use the ADA Type 2 Diabetes Treatment Algorithm Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP 8 ACOFP 55th Annual Convention & Scientific Seminars ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationDiabetes Family Medicine Board Review
Diabetes Family Medicine Board Review Sarah Kim, MD Associate Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March 21, 2018 No disclosures Diabetes Test Topics Majority Type
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSilvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine
Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationPhysiology of Normoglycemia
Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationDiabetes Family Medicine Board Review
Diabetes Family Medicine Board Review Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March 10, 2016 No disclosures Diabetes Test Topics Majority Type
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationWITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE
UPDATE ON THE NEW DIABETES MEDICATIONS AND HOW TO INCORPORATE INTO YOUR PRACTICE Amy DeGueme, MD, ECNU Madison Medical Affiliates 3/15/19 WITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE Which ones to
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationType 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18
Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA
More informationAntihyperglycemic Therapy in Type 2 Diabetes: What's Guiding Pharmacotherapy Choice?
Antihyperglycemic Therapy in Type 2 Diabetes: What's Guiding Pharmacotherapy Choice? Zach Weber, PharmD, BCPS, BCACP, CDE Live Activity Handout 4 slides per page Antihyperglycemic Therapy in Type 2 Diabetes:
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More information5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:
Insulin Workshop Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Holly Divine, PharmD, BCACP, BCGP, CDE,
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationNo disclosures. Diabetes Test Topics. Case #1. Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan
Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan No disclosures Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationUnderstanding Diabetes and Insulin Delivery Systems
Page 1 This program has been supported by an educational grant from Sanofi Aventis Scott K. Stolte, Pharm.D. Associate Dean, Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University Winchester,
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More information5/28/17. Medication Reconciliation. Disclosure. Objectives
5/28/17 Dana Saffel, Pharm D CPh, CGP, FASCP President, CEO. Medication Reconciliation Disclosure Dr. Saffel has no vested interest in or affiliation with any corporate organization offering financial
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationGLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationThe Role of Combination or Coformulation. Treatment of Type 2 Diabetes
The Role of Combination or Coformulation Products in the Treatment of Type 2 Diabetes Jennifer M. Trujillo, PharmD, FCCP, BCPS, CDE, BC-ADM University of Colorado Skaggs School of Pharmacy and Pharmaceutical
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More information